期刊文献+

应用导流杂交基因芯片技术检测人乳头状瘤病毒亚型的临床意义 被引量:17

Clinical Significance of HPV Genotypes Detection by using Flow Through Hybridization and Gene Chip
原文传递
导出
摘要 [目的]探讨人乳头状瘤病毒(HPV)不同型别的感染情况及其分型检测的临床意义。[方法]用导流杂交基因芯片技术对523例门诊首诊人群的宫颈脱落细胞标本进行HPV基因诊断和分型。[结果]①523例标本中HPV整体感染率为36.1%(189/523),单重感染率为31.4%(164/523);复合型别感染率为4.8%(25/523),包括2.9%(15/523)的双重感染及1.9%(10/523)的多重感染。②20-29岁和50-59岁组的感染率较高。③HPV阳性人群其宫颈高度病变的发生率(45.0%,85/189)显著高于HPV阴性人群(9.6%,32/334)。[结论]HPV分型检测对筛选宫颈高度病变有重要意义。导流杂交基因芯片技术适合临床筛查HPV感染及基因分型。 [Objective] To discuss the distribution of human papillomavirus(HPV) subtypes and the clinic significance.[Methods] Totally 523 cervix cellular specimen were analyzed by flow through hybridization and gene chip(HybrMax) to detect the genetic subtypes of HPV.[Results] ①General infection rate of HPV was 36.1%(189/523),single subtype infection rate was 31.4%(164/523),and complex subtypes infection rate was 4.8%(25/523),which involved 2.9%(15/523) dual-subtype infection and 1.9%(10/523) multi-subtype infection.②The rates for age groups 20-29 and 50-59 were higher than the others.③The prevalence of high cervical lesion(45.0%,85/189) in positive population was significantly higher than that in negative population(9.6%,32/334).[Conclusion] The detection of HPV subtypes is significant to screen the potential cervical lesion and HybrMax technology is suitable for clinical screening of HPV infection and gene typing.
出处 《海峡预防医学杂志》 CAS 2010年第1期4-7,共4页 Strait Journal of Preventive Medicine
基金 福建省医学创新课题(No.2009-CXB-33) 2007年度留学人员科技活动项目择优资助经费(人发[2001]33号)
关键词 宫颈疾病 人乳头状瘤病毒(HPV) 基因型 导流杂交基因芯片技术 Cervical Disease Human Papillomavirus Gene subtype Cervical lesion Hybridization and gene chip(HybrMax)
  • 相关文献

参考文献8

二级参考文献43

  • 1Gui-fang He,Mei-lu Blan,Ying Wang,Xiao-yan Liu.CERVICAL CYTOLOGICAL SCREENING AND MANAGEMENT IN PREGNANT AND POSTPARTUM WOMEN[J].Chinese Medical Sciences Journal,2005,20(4):242-246. 被引量:4
  • 2Huang S,Afonina I,Miller BA,et al.Huamn papillomavirus types 52 and 58 are prevalent in cervical cancer from Chinese women.Int J Cancer,1997,73:775-776.
  • 3Clifford GM,Smith JS,Plummer M,et al.Human papillomavirus types in invasive cervical cancer worldwide:a meta-analysis.Br J Cancer,2003,88:63-73.
  • 4McLachlin CM.Human Papillomavirus in cervical neroplasia.Role,risk factors and implications.Clin Lab Med,2000,20:257-270.
  • 5Masumoto N,Fujii T,Ishikawa M,et al.Dominant human papillomavirus 16 infection in cervical neoplasia in young Japanese women;study of 881 outpatients.Gynecol Oncol,2004,94:509-514.
  • 6Stanczuk GA,Kay P,Sibanda E,et al.Typing of human papillomavirus in Zimbabwean patients with invasive cancer of the uterine cervix.Acta Obstet Gynecol Scand,2003,82:762-766.
  • 7Poljak M,Marin IJ,Seme K,et al.Hybrid Capture Ⅱ Test detects at lease 15 human papillomvirus genotypes not included in its current high-risk probe cocktail.J Clin Virol,2002,25:S89-S97.
  • 8Dell G,Gaston K.Human papillomaviruses and their role in cervical cancer.Cell Mol Life Sci,2001,58:1923-1942.
  • 9Lo KW,Wong YF,Chan MK,et al.Prevalence of human papillomavirus in cervical cancer:a multicenter study in China.Int J Cancer,2002,100:327-331.
  • 10[2]Anttila A, Pukkala E, Sderman B, et al.Effect of organized screening on cervical cancer incidence and mortality in Finland, 1963-1995: Recent increase in cervical cancer incidence.Int J Cancer, 1999,83:59-65.

共引文献247

同被引文献117

引证文献17

二级引证文献108

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部